Rexahn Pharmaceuticals (NASDAQ:REXN) Cut to Hold at Zacks Investment Research
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Other analysts also recently issued reports about the stock. HC Wainwright downgraded shares of Rexahn Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 7th. ValuEngine upgraded shares of Rexahn Pharmaceuticals from a hold rating to a buy rating in a report on Monday, October 7th. Finally, Ifs Securities downgraded shares of Rexahn Pharmaceuticals from a strong-buy rating to a market perform rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $12.63.
Rexahn Pharmaceuticals (NASDAQ:REXN) last announced its earnings results on Wednesday, August 7th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.34. Analysts forecast that Rexahn Pharmaceuticals will post -2.26 earnings per share for the current year.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer.
Further Reading: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.